GSK 461364
Alternative Names: 461364; GSK-461364; GSK461364ALatest Information Update: 09 Jul 2025
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antineoplastics; Small molecules; Thiophenes
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics data from preclinical studies in solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in United Kingdom (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV, Infusion)